טקסוטר

Country: ইস্রায়েল

ভাষা: হিব্রু

সূত্র: Ministry of Health

সক্রিয় উপাদান:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

থেকে পাওয়া:

SANOFI - AVENTIS ISRAEL LTD

এটিসি কোড:

L01CD02

ফার্মাসিউটিকাল ফর্ম:

CONCENTRATE FOR SOLUTION FOR INFUSION

প্রশাসন রুট:

I.V

Manufactured by:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Therapeutic group:

DOCETAXEL

থেরাপিউটিক ইঙ্গিত:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

অনুমোদন তারিখ:

2012-11-01